Listed by the USPTO as VANHORN, ABIGAIL LOUISE
Tech Center 1600 • Art Units: 1616 1633 1635 1636 1637
This examiner grants 47% of resolved cases
VANHORN, ABIGAIL LOUISE has resolved 1223 cases in technology center 1600 and art unit 1616. The allowance rate is 46.8%, and the median time to allowance is 1366 days. Interviews are associated with a 22.7% lift in the allowance rate. The high resolved-case volume provides a substantial basis for reviewing the profile's prosecution tendencies.
Entrada Therapeutics Inc., University of Massachusetts, and Board of Regents of the University of Texas System are the listed leading companies. FENWICK & WEST LLP, GOODWIN PROCTER LLP, and Lathrop GPM LLP are the listed leading firms. Practitioners can use these entities to identify recurring stakeholders and consider interview practice as one component of an overall response strategy.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19568680 | YEAST CELL WALL PARTICLE ENCAPSULATION OF BIODEGRADABLE PRO-PAYLOADS | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17777386 | COMPOSITIONS AND METHODS FOR ON-DEMAND RELEASE OF ANTIMICROBIAL AGENTS | Non-Final OA | University of Massachusetts |
| 18698888 | LIPID NANOPARTICLES FOR DRUG DELIVERY TO MICROGLIA IN THE BRAIN | Non-Final OA | Massachusetts Institute of Technology |
| 15367356 | COMPOSITION FOR HAIR FRIZZ REDUCTION | Non-Final OA | The Procter & Gamble Company |
| 17822746 | EFFICIENT GENOME EDITING IN PRIMARY MYELOID CELLS | Final Rejection | Genentech, Inc. |
| 18271536 | TREATING DISEASES AND IMPROVING NUCLEIC ACID DELIVERY | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18419370 | COMPOSITIONS, METHODS AND USES FOR TREATING CYSTIC FIBROSIS AND RELATED DISORDERS | Non-Final OA | The Board of Regents of The University of Texas System |
| 18508192 | LIPOCATIONIC DENDRIMERS AND USES THEREOF | Non-Final OA | The Board of Regents of The University of Texas System |
| 17906134 | COMPOSITIONS AND METHODS COMPRISING IMPROVED GUIDE RNAs | Final Rejection | Cornell University |
| 17791504 | LONG-ACTING THERAPEUTIC AGENT COMBINATIONS AND METHODS THEREOF | Final Rejection | University of Washington |
| 18273501 | CRISPR-ASSOCIATED BASED-EDITING OF THE COMPLEMENTARY STRAND | Final Rejection | Wageningen Universiteit |
| 18248988 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Final Rejection | SANOFI |
| 17925225 | CUG REPEAT SEQUENCE BINDING AGENT | Final Rejection | OSAKA UNIVERSITY |
| 18562095 | OLIGO-MODIFIED NUCLEOTIDE ANALOGUES FOR NUCLEIC ACID PREPARATION | Non-Final OA | ILLUMINA, INC. |
| 18028751 | PATIENT SELECTION BIOMARKERS FOR TREATMENT WITH ULK INHIBITORS | Final Rejection | Salk Institute for Biological Studies |
| 18160114 | INTEGRIN LIGANDS AND USES THEREOF | Non-Final OA | Arrowhead Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy46.8% of resolved applications examined by Abigail Louise Vanhorn were allowed (1,223 resolved cases), compared with 24.5% across Art Unit 1616 over the last five years.
This examiner's interview lift is +22.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Abigail Louise Vanhorn took 1,366 days on average from filing to allowance.
Abigail Louise Vanhorn examines applications in Art Unit 1616 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
